Emmett Cunningham is the founder of Eyconis. Eyconis has raised $150M in total funding. Backed by Frazier Life Sciences, RA Capital Management, venBio.
Emmett Cunningham is the Executive Chairman of Eyconis, a company formed to develop, manufacture, and commercialize TransCon ophthalmology assets. Eyconis will initially focus on treatments for wet age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and geographic atrophy (GA). Cunningham is also a Senior Partner at HealthQuest Capital.
Full founder directory · Investor directory · Company funding database · Fundraising library